Telehealth providers in Kansas

Verified telehealth providers serving Kansas

Telehealth prescribing rules in Kansas

The Kansas Telemedicine Act (2018) defines telemedicine as care delivered by real-time two-way interactive audio, visual, or audio-visual communication, including secure video conferencing or store-and-forward technology used to provide or support care (K.S.A. 40-2,211). K.S.A. 40-2,212 states that telemedicine may be used to establish a valid provider-patient relationship, that in-person standards of practice and conduct apply, that the provider must give guidance on follow-up care, and that with patient consent the provider must send a report to the patient's primary care or treating physician within three business days. K.S.A. 40-2,214 directed the State Board of Healing Arts to adopt rules on prescribing by telemedicine, which the Board did in K.A.R. 100-77. Because the statutory definition centers on real-time interaction and treats store-and-forward as supporting care, it is unclear whether a purely asynchronous first encounter satisfies Kansas law. K.A.R. 100-77 has three short regulations: 100-77-1 adopts the statutory definitions, 100-77-2 deems telemedicine rendered where the patient is, and 100-77-3 says the same laws that apply to in-person prescribing, including for controlled substances, apply to prescribing by telemedicine. None of them addresses asynchronous-only prescribing, so async_prescribing_allowed is left unknown. [2] [3] [7] [8] [9]

Compounded GLP-1 access in Kansas

Kansas patients using telehealth GLP-1 programs should confirm the prescriber holds a Kansas license and that the dispensing pharmacy has a Kansas nonresident pharmacy registration under K.S.A. 65-1657. The Kansas Board of Pharmacy's statement on compounding and dispensing GLP-1 and GIP receptor agonists (last updated August 26, 2026) says semaglutide and tirzepatide are no longer in shortage, that no salt form of either may be used in a compounded drug, and that even when compounding is otherwise allowed, a non-pharmaceutical grade bulk substance or one not made in an FDA-registered establishment is prohibited. It also says pre-printed or check-box prescriptions may not document the patient-specific need that copies of approved drugs require, and that retatrutide and cagrilintide cannot be used to compound under federal law. [6] [10] [12] [13]

Research use only sellers in Kansas

K.S.A. 65-1657 bars unregistered nonresident pharmacies from shipping prescription drugs into Kansas and from advertising to Kansas residents. The Kansas Board of Pharmacy's GLP-1 statement adds that compounding pharmacies must use pharmaceutical-grade active ingredients, not research use, investigational, food, or supplement grade, with a certificate of analysis naming the original manufacturer, and that a pharmacist may not dispense a product compounded in a non-compliant manner. [6] [10] [14]